Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00897975
Other study ID # FWA00005390 Chestnut HillHC
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received May 11, 2009
Last updated July 14, 2011
Start date July 2009
Est. completion date July 2011

Study information

Verified date November 2009
Source Chestnut Hill Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Red yeast rice may be useful to lower cholesterol, especially in a population of patients who cannot tolerate traditional therapy with statins.

The addition of an over-the-counter phytosterol to red yeast rice may offer additional lipid lowering benefits when compared to red yeast rice alone.

These supplements will be given to all participants. Up to one-half will enroll in a lifestyle intervention program called Change of Heart and will be compared to patients who do not participate in the program. The study will last one year.


Description:

Although recent studies have shown that red yeast rice is an effective therapy in the treatment of hyperlipidemia, additional supplements may be required to lower cholesterol to levels that have been associated with decreased coronary events. Specifically a target has been to lower low-density lipoprotein-C (LDL-C) to levels below 100 mg/dl. Red yeast rice has been found to be effective in lowering cholesterol in the context of the Change of Heart Program, where participants are encouraged to make significant lifestyle changes. This has been documented in two recent trials that we have published in the past year in the Mayo Clinic Proceedings (July 2008) and The Annals of Internal Medicine (in press). Clinically, we have found it necessary to add a phytosterol supplement to red yeast rice to lower LDL-C levels below 100 mg/dl. There has been a great deal of interest in phytosterols in both the lay and medical press in the past several years. This over the counter supplement lowers cholesterol by acting in the intestine to decrease the absorption of cholesterol. As it is not absorbed, there have not been any reports of significant side effects. The purpose of this study is to examine the lipid lowering effects of red yeast rice with and without adding a phytosterol. Some participants will attend the Change of Heart Program and take these supplements. Another group of participants will take the same supplements, with their usual medical care, but not enroll in the Change of Heart Program. The study will last one year, and participants will have been intolerant of statins in the past.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date July 2011
Est. primary completion date November 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Men and women age > 21

- LDL > 100 and physician suggestion to take statin

- Subject complains of muscle weakness or aching which he/she or his/her physician feels may be attributable to statin therapy

- Having stopped a statin drug for personal reasons and not willing to restart this medication

- Refusal to take a statin as prescribed by personal physician

- CPK < 400

- Not taking any cholesterol lowering medication, red yeast rice extract or a phytosterol product for at least 1 month prior to initiation of trial

- Ability to exercise without physical restrictions

- Ability to attend 12 week consecutive Change of Heart lifestyle education sessions

- Liver function studies normal at baseline

- Subject willing to remain off the dietary supplement CoQ10 for duration of trial

- TSH must be normal

Exclusion Criteria:

- A history of muscle damage (CPK > 400 IU) on statin therapy

- Any active cardiac problem including chest pain, angina, shortness of breath with minimal activity, or unstable angina/acute coronary syndrome within one year

- Known intolerance to one of the study drugs

- Physical limitation preventing aerobic exercise program, such as severe arthritis, peripheral vascular disease, congestive heart failure, or symptom limiting pulmonary disease

- Uncontrolled hypertension (defined as SBP > 180 mmHg or DBP > 100 mmHg

- Heart attack, bypass surgery, or angioplasty/stent within 1 year of study

- Triglyceride level more than 400 mg/dl

- Underlying musculoskeletal disorder preventing muscle testing

- Taking other medicines including: cyclosporine, erythromycin or other macrolide antibiotics; fluconazole; niacin; fibrates; or > 16 oz. of grapefruit juice daily

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
red yeast rice
600 mg 3 capsules bid
Drug:
phytosterol
phytosterol 450 mg 2 tabs bid with food
Behavioral:
therapeutic lifestyle program
TLC - 12 weeks
Drug:
placebo
placebo

Locations

Country Name City State
United States Abington Memorial Hospital Abington Pennsylvania
United States Chestnut Hill Hospital Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Chestnut Hill Health System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary LDL cholesterol levels one year
Secondary myalgia compared to prior statin usage one year
Secondary other lipoprotein levels one year
Secondary weight loss in TLC program vs. baseline one year
See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed NCT02927184 - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Phase 2
Completed NCT04640012 - Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects Phase 1
Completed NCT03213288 - Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status N/A
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02979704 - A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia Phase 2/Phase 3
Completed NCT02569814 - A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin Phase 1
Completed NCT02280590 - Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia Phase 4
Completed NCT02428998 - Safety for 24 Weeks Intake of Korean Red Ginseng in Adults N/A
Completed NCT01678183 - Financial Incentives for Medication Adherence N/A
Completed NCT01694446 - Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose N/A
Completed NCT01426412 - A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol Phase 1
Completed NCT01131832 - Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols Phase 4
Completed NCT00534105 - Lipid Metabolism in Gestational Diabetes N/A
Completed NCT00758303 - A Study to Evaluate the Lipid Regulating Effects of TRIA-662 Phase 2/Phase 3
Recruiting NCT00408824 - Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study) N/A
Completed NCT00362206 - Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin Phase 3
Terminated NCT00299169 - Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes Phase 4
Completed NCT00414986 - Using Learning Teams for Reflective Adaptation for Diabetes and Depression N/A
Completed NCT00381992 - Risk Assessment of Long-Haul Truck Drivers N/A